Outlook Therapeutics (OTLK) Expected to Announce Quarterly Earnings on Wednesday

Posted by Defense World Staff on Feb 11th, 2025

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last announced its quarterly earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Outlook Therapeutics Stock Down 1.2 %

Shares of OTLK stock opened at $1.69 on Tuesday. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The firm has a fifty day moving average of $1.87 and a 200-day moving average of $4.67. The company has a market capitalization of $54.05 million, a price-to-earnings ratio of -0.19 and a beta of 0.58.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Guggenheim reaffirmed a “buy” rating and set a $12.00 price target on shares of Outlook Therapeutics in a research report on Friday, January 17th. Finally, BTIG Research lowered their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.40.

Get Our Latest Stock Analysis on Outlook Therapeutics

Outlook Therapeutics Company Profile

(Get Free Report)

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.